StockNews.com started coverage on shares of LifeVantage (NASDAQ:LFVN – Get Rating) in a research report issued to clients and investors on Thursday. The firm set a “strong-buy” rating on the stock.
LifeVantage Trading Down 10.4 %
LFVN opened at $4.06 on Thursday. The stock’s 50 day simple moving average is $3.65 and its 200-day simple moving average is $3.76. The stock has a market cap of $51.97 million, a PE ratio of -67.67 and a beta of 1.09. LifeVantage has a 1 year low of $3.04 and a 1 year high of $4.92.
Hedge Funds Weigh In On LifeVantage
Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC increased its holdings in LifeVantage by 0.3% in the second quarter. Renaissance Technologies LLC now owns 974,318 shares of the company’s stock valued at $4,238,000 after purchasing an additional 3,300 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in LifeVantage by 4.6% in the first quarter. Dimensional Fund Advisors LP now owns 271,614 shares of the company’s stock valued at $1,293,000 after purchasing an additional 11,964 shares during the last quarter. BlackRock Inc. increased its holdings in LifeVantage by 10.5% in the first quarter. BlackRock Inc. now owns 249,547 shares of the company’s stock valued at $1,188,000 after purchasing an additional 23,788 shares during the last quarter. EP Wealth Advisors LLC bought a new stake in LifeVantage in the first quarter valued at about $234,000. Finally, State Street Corp increased its holdings in LifeVantage by 7.6% in the first quarter. State Street Corp now owns 46,191 shares of the company’s stock valued at $220,000 after purchasing an additional 3,281 shares during the last quarter. Institutional investors and hedge funds own 29.69% of the company’s stock.
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region, and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs.
- Get a free copy of the StockNews.com research report on LifeVantage (LFVN)
- Toll Brothers Rises On Results, But The Roof Is In Place
- It’s Time To Try On VF Corporation’s 6% Yield
- PetCo Management Getting it Right? Earnings Beat Says Yes
- Axcelis Stock In Buy Range After Chart Breakout, Strong Guidance
- Kohl’s 10% Yield Comes Into High Fashion
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.